J. Divisova et al., Effect of ACE inhibitor captopril and L-arginine on the metabolism and on ischemia-reperfusion injury of the isolated rat heart, PHYSL RES, 50(2), 2001, pp. 143-152
We investigated the effects of in vivo treatment with the angiotensin-conve
rting enzyme inhibitor (ACE-I) captopril and/or of in vitro administration
of L-arginine on the metabolism and ischemia-reperfusion injury of the isol
ated perfused rat myocardium. Captopril (50 mg/l in drinking water, 4 weeks
) raised the myocardial content of glycogen. After 25-min global ischemia,
captopril treatment, compared with the controls, resulted in lower rates of
lactate dehydrogenase release during reperfusion (8.58 +/-1.12 vs. 13.39 /-1.88 U/heart/30 min, p<0.05), lower myocardial lactate contents (11.34<pl
us/minus>0.93 vs. 21.22 +/-4.28 mu mol/g d.w., p<0.05) and higher coronary
flow recovery (by 25 %), and prevented the decrease of NO release into the
perfusate during reperfusion. In control hearts L-arginine added to the per
fusate (1 mmol/l) 10 min before ischemia had no effect on the parameters ev
aluated under our experimental conditions, presumably because of sufficient
saturation of the myocardium with L-arginine. In the hearts of captopril-t
reated rats, L-arginine further increased NO production during reperfusion
and the cGMP content before ischemia. Our results have shown that long-term
captopril treatment increases the energy potential and has a beneficial ef
fect on tolerance of the isolated heart to ischemia. L-arginine added into
the perfusate potentiates the effect of captopril on the NO signaling pathw
ay.